Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies.

ABSTRACT:

Importance

The expansion in the number of disease-modifying therapies (DMTs) for immune-mediated neurologic diseases raises critical questions about trends in their use and cost over time and whether this growth could be contributing to escalating financial burdens within the Medicare system.

Objective

To examine trends in claims and Medicare Part D payments for DMTs for immune-mediated neurologic diseases.

Design and setting

This retrospective economic evaluation analyzed Medicare Part D Prescriber Public Use Files from January 1, 2013, to December 31, 2022, restricting to prescription drug claims categorized under the clinician-defined neurology taxonomy. Only prescription drugs used as DMTs for multiple sclerosis, neuromyelitis optica spectrum disorder, and other i

SUBMITTER: Wong KH 

PROVIDER: S-EPMC12538365 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature